Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Chmp symbols : ABBV save search
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2023-07-21 (Crawled : 09:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
tepkinly abbvie chmp positive treatment
AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
Published: 2023-06-23 (Crawled : 12:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.08%
H: 1.01%
C: -1.01%
abbvie chmp positive treatment migraine
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Published: 2023-02-27 (Crawled : 08:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.36%
H: 0.97%
C: 0.67%
rinvoq treatment disease abbvie chmp positive
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Published: 2022-09-19 (Crawled : 08:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.29%
H: 0.15%
C: -0.68%
skyrizi treatment disease chmp risankizumab positive
CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
Published: 2022-06-27 (Crawled : 07:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 1.55%
H: 0.0%
C: 0.0%
rinvoq treatment active chmp approval
CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis
Published: 2022-05-23 (Crawled : 07:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
rinvoq treatment chmp approval ulcerative colitis
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
Published: 2021-10-15 (Crawled : 13:15) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.22%
H: 0.74%
C: 0.16%
treatment europe positive risankizumab chmp
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Published: 2021-06-25 (Crawled : 07:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -1.6%
H: 0.61%
C: 0.07%
treatment dermatitis approval chmp atopic dermatitis
AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Published: 2021-04-23 (Crawled : 14:00) - biospace.com/
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.31%
H: 1.88%
C: 1.52%
myeloid leukemia positive therapy leukemia chmp acute myeloid leukemia
CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Published: 2020-12-11 (Crawled : 13:13) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.45%
H: 0.38%
C: -0.63%
approval treatment chmp
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.